{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:05:58Z","timestamp":1789549558969,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,5]]},"DOI":"10.7759\/cureus.51729","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T07:41:46Z","timestamp":1704526906000},"source":"Crossref","is-referenced-by-count":2,"title":["A Case of Late-Onset Neutropenia in Relapsing-Remitting Multiple Sclerosis Following Ocrelizumab Therapy"],"prefix":"10.7759","author":[{"given":"Reema A","family":"Alabdulqader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafa","family":"Alnasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussain J","family":"Aljubran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan H","family":"Alkhulaif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418773025","article-title":"Ocrelizumab: a new milestone in multiple sclerosis therapy","volume":"11","author":"Mulero P","year":"2018","unstructured":"Mulero P, Midaglia L, Montalban X. Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord. 2018, 11:1756286418773025. 10.1177\/1756286418773025","journal-title":"Ther Adv Neurol Disord"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/1756285615601933","article-title":"The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects","volume":"9","author":"Sorensen PS","year":"2016","unstructured":"Sorensen PS, Blinkenberg M. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord. 2016, 9:44-52. 10.1177\/1756285615601933","journal-title":"Ther Adv Neurol Disord"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0488-6","article-title":"Efficacy and safety of the newer multiple sclerosis drugs approved since 2010","volume":"32","author":"Faissner S","year":"2018","unstructured":"Faissner S, Gold R. Efficacy and safety of the newer multiple sclerosis drugs approved since 2010. CNS Drugs. 2018, 32:269-87. 10.1007\/s40263-018-0488-6","journal-title":"CNS Drugs"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102155","article-title":"Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab","volume":"43","author":"Auer M","year":"2020","unstructured":"Auer M, Bsteh G, Hegen H, et al.. Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab. Mult Scler Relat Disord. 2020, 43:102155. 10.1016\/j.msard.2020.102155","journal-title":"Mult Scler Relat Disord"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116603","article-title":"Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: a case report and review of the literature","volume":"409","author":"Zanetta C","year":"2020","unstructured":"Zanetta C, Robotti M, Nozzolillo A, et al.. Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: a case report and review of the literature. J Neurol Sci. 2020, 409:116603. 10.1016\/j.jns.2019.116603","journal-title":"J Neurol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181f2caef","article-title":"Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature","volume":"89","author":"Wolach O","year":"2010","unstructured":"Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore). 2010, 89:308-18. 10.1097\/MD.0b013e3181f2caef","journal-title":"Medicine (Baltimore)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3313-y","article-title":"Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature","volume":"35","author":"Monaco WE","year":"2016","unstructured":"Monaco WE, Jones JD, Rigby WF. Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature. Clin Rheumatol. 2016, 35:2457-62. 10.1007\/s10067-016-3313-y","journal-title":"Clin Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102019","article-title":"Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases","volume":"41","author":"Rigal J","year":"2020","unstructured":"Rigal J, Ciron J, L\u00e9pine Z, Biotti D. Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases. Mult Scler Relat Disord. 2020, 41:102019. 10.1016\/j.msard.2020.102019","journal-title":"Mult Scler Relat Disord"},{"key":"ref9","article-title":"Highlights of Prescribing Information","year":"2017","unstructured":"Highlights of Prescribing Information. Food and Drug Administration, 2017."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5299","article-title":"Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: a case report","volume":"10","author":"Rauniyar R","year":"2022","unstructured":"Rauniyar R, Rauniyar R, Agrawal A, Yadav S, Avula S. Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: a case report. Clin Case Rep. 2022, 10:e05299. 10.1002\/ccr3.5299","journal-title":"Clin Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1941874420936438","article-title":"Severe delayed-onset neutropenia induced by ocrelizumab","volume":"11","author":"Baird-Gunning J","year":"2021","unstructured":"Baird-Gunning J, Yun J, Stevenson W, Ng K. Severe delayed-onset neutropenia induced by ocrelizumab. Neurohospitalist. 2021, 11:59-61. 10.1177\/1941874420936438","journal-title":"Neurohospitalist"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006924","article-title":"Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis","volume":"92","author":"Cohen BA","year":"2019","unstructured":"Cohen BA. Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis. Neurology. 2019, 92:435-6. 10.1212\/WNL.0000000000006924","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.38","article-title":"Autoimmune and other acquired neutropenias","volume":"2016","author":"Newburger PE","year":"2016","unstructured":"Newburger PE. Autoimmune and other acquired neutropenias. Hematology Am Soc Hematol Educ Program. 2016, 2016:38-42. 10.1182\/asheducation-2016.1.38","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref14","article-title":"Drug-induced neutropenia: a focus on rituximab-induced late-onset neutropenia","volume":"41","author":"Moore DC","year":"2016","unstructured":"Moore DC. Drug-induced neutropenia: a focus on rituximab-induced late-onset neutropenia. P T. 2016, 41:765-8.","journal-title":"P T"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/211377-a-case-of-late-onset-neutropenia-in-relapsing-remitting-multiple-sclerosis-following-ocrelizumab-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:16:27Z","timestamp":1707509787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/211377-a-case-of-late-onset-neutropenia-in-relapsing-remitting-multiple-sclerosis-following-ocrelizumab-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.51729","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,5]]}}}